Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report
This is the first case of an R2034Ter ATM mutant PDAC with sustained clinical response under olaparib maintenance therapy reported. In select cases, ATM, a member of the BRCA pathway, might be a druggable target in pancreatic cancer.
Authors
- Alexander B. Philipp (ORCID: https://orcid.org/0000-0002-0215-9977)
- Julia V. Mayerle (ORCID: https://orcid.org/0000-0002-3666-6459)
- Volker Heinemann (ORCID: https://orcid.org/0000-0002-1349-3321)
- Daniel Markwardt
- Daniel Rössler
- C. Benedikt Westphalen (ORCID: https://orcid.org/0000-0002-5310-3754)
- Alexander Kleger (ORCID: https://orcid.org/0000-0003-0592-5232)
- Maximilian Niyazi (ORCID: https://orcid.org/0000-0002-7711-9486)
- Andreas Jung (ORCID: https://orcid.org/0000-0001-5270-9108)
- Georg Beyer (ORCID: https://orcid.org/0000-0002-7607-8264)
- Kathrin Heinrich (ORCID: https://orcid.org/0000-0003-3580-2313)
- Paul Rogowski (ORCID: https://orcid.org/0000-0003-3351-8896)
- Simon Sirtl (ORCID: https://orcid.org/0000-0002-6047-334X)
- Katarina Ondrejkova
- Marianne Angelberger
- Marlies Vornhülz
Institutions
- LMU Klinikum (DE)
- Centre de Coopération Universitaire Franco-Bavarois (DE)
- University Hospital Ulm (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- University of Tübingen (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1159/000545975
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05